OH2 Oncolytic Viral Therapy Via Transcatheter Intraarterial Infusion in Patients with Advanced Liver Cancer

This study tests whether OH2 — an oncolytic virus (a virus engineered to infect and destroy cancer cells) — can be safely and effectively delivered directly into the liver's blood supply (via a catheter) in patients with advanced liver cancer that has not responded to standard treatment. **You may be eligible if...** - You are 18–75 years old with primary or metastatic liver cancer confirmed by biopsy - Your cancer has not responded to standard treatments or you are not eligible for them - Your liver function is adequate (Child-Pugh grade A or B) - You are in good physical condition (ECOG 0 or 1) **You may NOT be eligible if...** - You have active hepatitis B or C, HIV, or another uncontrolled infection - You have previously received oncolytic virus therapy - You have blood clotting problems or active bleeding - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.